INT15376

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.70
First Reported 1991
Last Reported 2011
Negated 11
Speculated 2
Reported most in Body
Documents 215
Total Number 217
Disease Relevance 168.54
Pain Relevance 5.23

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (ERBB2) signal transduction (ERBB2) plasma membrane (ERBB2)
nucleus (ERBB2) cytoplasm (ERBB2)
Anatomy Link Frequency
lymph node 10
MCF-7 8
node 8
axillary 6
MCF7 4
ERBB2 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 18 99.30 Very High Very High Very High
palliative 106 98.68 Very High Very High Very High
cytokine 43 97.16 Very High Very High Very High
Dismenorea 1 94.80 High High
Pain 96 94.68 High High
abdominal pain 11 92.88 High High
imagery 128 92.24 High High
Opioid 2 91.16 High High
intrathecal 10 90.68 High High
cINOD 7 90.08 High High
Disease Link Frequency Relevance Heat
Cancer 8052 100.00 Very High Very High Very High
Disease 2488 100.00 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 1915 100.00 Very High Very High Very High
Breast Cancer 6069 99.98 Very High Very High Very High
Metastasis 1396 99.98 Very High Very High Very High
Stomach Cancer 674 99.98 Very High Very High Very High
Carcinoma 592 99.98 Very High Very High Very High
Ductal Carcinoma 94 99.98 Very High Very High Very High
Ovarian Cancer 362 99.96 Very High Very High Very High
Endometroid Carcinoma 132 99.84 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It should also prove to be useful in the treatment of subsets of patients with other adenocarcinomas whose tumors over-express HER2.
Positive_regulation (over) of Gene_expression (express) of HER2 associated with adenocarcinoma and cancer
1) Confidence 0.70 Published 1999 Journal Cancer Biother. Radiopharm. Section Abstract Doc Link 10850281 Disease Relevance 0.69 Pain Relevance 0
The drug inhibits the growth of human breast cancer cells overexpressing HER2 in vitro and in vivo.
Positive_regulation (overexpressing) of Gene_expression (overexpressing) of HER2 associated with breast cancer
2) Confidence 0.70 Published 1999 Journal BioDrugs Section Abstract Doc Link 18031170 Disease Relevance 0.58 Pain Relevance 0.04
In patients with metastatic breast cancer whose tumours overexpressed HER2, trastuzumab (4 mg/kg loading dose then 2 mg/kg/week by intravenous infusion) produced objective responses in 21% of 213 patients.
Positive_regulation (overexpressed) of Gene_expression (overexpressed) of HER2 associated with cancer and advanced or metastatic breast cancer
3) Confidence 0.70 Published 1999 Journal BioDrugs Section Abstract Doc Link 18031170 Disease Relevance 0.67 Pain Relevance 0.05
The beneficial effects were greatest in patients with the greatest degree (3+) of HER2 protein overexpression.
Positive_regulation (overexpression) of Gene_expression (overexpression) of HER2 protein
4) Confidence 0.70 Published 1999 Journal Clin Ther Section Abstract Doc Link 10211534 Disease Relevance 1.12 Pain Relevance 0.12
In vitro and in vivo preclinical studies have shown that administration of trastuzumab alone or in combination with paclitaxel or carboplatin significantly inhibits the growth of breast tumor-derived cell lines that overexpress the HER2 gene product.
Positive_regulation (overexpress) of Gene_expression (overexpress) of HER2 gene associated with breast cancer
5) Confidence 0.70 Published 1999 Journal Clin Ther Section Abstract Doc Link 10211534 Disease Relevance 0.35 Pain Relevance 0
Trastuzumab has been approved by the US Food and Drug Administration as a single agent for the treatment of patients who have metastatic breast cancer involving overexpression of the HER2 protein and who have received 1 or more chemotherapy regimens; in combination with paclitaxel, it has been approved for the treatment of such patients who have not received chemotherapy.
Positive_regulation (overexpression) of Gene_expression (overexpression) of HER2 protein associated with advanced or metastatic breast cancer
6) Confidence 0.70 Published 1999 Journal Clin Ther Section Abstract Doc Link 10211534 Disease Relevance 1.91 Pain Relevance 0.26
It has been demonstrated that HER2 overexpression correlates with tumor invasion and lymph node metastasis, and thus indicates a poor prognosis [71, 73–75].
Positive_regulation (overexpression) of Gene_expression (overexpression) of HER2 in lymph node associated with cancer and metastasis
7) Confidence 0.70 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.56 Pain Relevance 0
In breast cancer, it is generally thought that HER2 overexpression is the direct result of gene amplification [59].
Positive_regulation (overexpression) of Gene_expression (overexpression) of HER2 associated with breast cancer
8) Confidence 0.70 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.66 Pain Relevance 0
The data on HER2 overexpression in esophageal cancer are variable, with most studies showing HER2 overexpression in 9%–60% of cases, whereas other reports failed to observe HER2 expression [72].
Positive_regulation (overexpression) of Gene_expression (overexpression) of HER2 associated with esophageal cancer
9) Confidence 0.70 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.29 Pain Relevance 0
In addition, differences between HER2 overexpression in European and Asian/South-American populations (22–28% versus 3–15%, resp.) have been reported by some studies [68], but others have found these differences to be less substantial [69].
Positive_regulation (overexpression) of Gene_expression (overexpression) of HER2
10) Confidence 0.70 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.94 Pain Relevance 0
The reason for the selective overexpression of HER2 in intestinal-type gastric cancers is complex and needs further investigation.
Positive_regulation (overexpression) of Gene_expression (overexpression) of HER2 associated with stomach cancer
11) Confidence 0.70 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.39 Pain Relevance 0
With regard to this testing, overexpression of the HER2 protein seems to possess the best predictive value.
Positive_regulation (overexpression) of Gene_expression (overexpression) of HER2 protein
12) Confidence 0.70 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.86 Pain Relevance 0
Reported rates of HER2 overexpression in gastroesophageal cancer vary widely (2–45%) due to small sample sizes, differences in patient populations and methodological and scoring differences between studies [45, 62–67].
Positive_regulation (overexpression) of Gene_expression (overexpression) of HER2 associated with cancer
13) Confidence 0.70 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.95 Pain Relevance 0
A HER2 expression at the 2+ level required confirmation by the proof of a HER2 gene amplification by FISH.
Positive_regulation (required) of Gene_expression (expression) of HER2
14) Confidence 0.69 Published 2008 Journal Cancer Chemother Pharmacol Section Body Doc Link PMC2688618 Disease Relevance 0.29 Pain Relevance 0
It is important that overexpression of HER2 also identifies those women who may benefit from the targeted drug trastuzumab, and those who do better with chemotherapy regimens that contain a drug of the anthracycline class [6].
Positive_regulation (overexpression) of Gene_expression (overexpression) of HER2
15) Confidence 0.69 Published 2008 Journal Cancer Chemother Pharmacol Section Body Doc Link PMC2688618 Disease Relevance 0.85 Pain Relevance 0
Breast cancers that make high levels of the transmembrane protein kinase HER2 (i.e., those that overexpress HER2) have a poorer prognosis as compared to those that either do not make this protein or make lower levels [6].
Positive_regulation (overexpress) of Gene_expression (overexpress) of HER2 associated with breast cancer
16) Confidence 0.69 Published 2008 Journal Cancer Chemother Pharmacol Section Body Doc Link PMC2688618 Disease Relevance 0.84 Pain Relevance 0
The ErbB2 receptor tyrosine kinase is often overexpressed in human malignancies and causally involved in transformation.
Positive_regulation (overexpressed) of Gene_expression (overexpressed) of ErbB2
17) Confidence 0.69 Published 1999 Journal Hybridoma Section Abstract Doc Link 10211791 Disease Relevance 0.43 Pain Relevance 0
Approximately 20%–25% of breast cancers overexpress human epidermal receptor type 2 (ErbB2 or HER2), which is associated with a more aggressive cancer and predicts poor clinical outcome (Slamon et al 1987).
Positive_regulation (overexpress) of Gene_expression (overexpress) of HER2 associated with cancer and breast cancer
18) Confidence 0.68 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727787 Disease Relevance 0.94 Pain Relevance 0
HER2 was overexpressed in 8 of these 21 initially HER2-negative patients (38%).
Positive_regulation (overexpressed) of Gene_expression (overexpressed) of HER2
19) Confidence 0.68 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2605098 Disease Relevance 1.01 Pain Relevance 0.07
In one patient, palliative chemotherapy was installed, combined with trastuzumab because of HER2/neu overexpression.
Positive_regulation (overexpression) of Gene_expression (overexpression) of HER2/neu associated with palliative
20) Confidence 0.67 Published 2007 Journal Ned Tijdschr Geneeskd Section Abstract Doc Link 17447590 Disease Relevance 0.72 Pain Relevance 0.50

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox